Abstract
© 2018 The AuthorsCOPD is a chronic lung disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. Furthermore, COPD is often characterized by extrapulmonary manifestations and comorbidities worsening COPD progression and quality of life. A neglected comorbidity in COPD management is mental health impairment defined by anxiety, depression and cognitive problems. This paper summarizes the evidence for impaired mental health in COPD and focuses on current pharmacological intervention strategies. In addition, possible mechanisms in impaired mental health in COPD are discussed with a central role for inflammation. Many comorbidities are associated with multi-organ-associated systemic inflammation in COPD. Considering the accumulative evidence for a major role of systemic inflammation in the development of neurological disorders, it can be hypothesized that COPD-associated systemic inflammation also affects the function of the brain and is an interesting therapeutic target for nutra- and pharmaceuticals.
| Original language | English |
|---|---|
| Pages (from-to) | 99-110 |
| Journal | European Journal of Pharmacology |
| Volume | 842 |
| DOIs | |
| Publication status | Published - 5 Jan 2019 |
| Externally published | Yes |
Funding
This work was supported by an LSH-TKI Lung Foundation grant 10.2.16.119 , 2017 ‘Food for thought and active lifestyle in COPD’.
| Funders | Funder number |
|---|---|
| LSH-TKI Lung Foundation | 10.2.16.119 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Psychological co-morbidities in COPD: Targeting systemic inflammation, a benefit for both?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver